These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27129215)

  • 21. 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.
    Mancini JA; Prasit P; Coppolino MG; Charleson P; Leger S; Evans JF; Gillard JW; Vickers PJ
    Mol Pharmacol; 1992 Feb; 41(2):267-72. PubMed ID: 1538707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors.
    Vickers PJ; Adam M; Charleson S; Coppolino MG; Evans JF; Mancini JA
    Mol Pharmacol; 1992 Jul; 42(1):94-102. PubMed ID: 1635556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors.
    Vickers PJ; Adam M; Charleson S; Abramovitz M; O'Neill G; Mancini JA
    J Lipid Mediat; 1993; 6(1-3):31-42. PubMed ID: 8357989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease.
    Lemurell M; Ulander J; Emtenäs H; Winiwarter S; Broddefalk J; Swanson M; Hayes MA; Prieto Garcia L; Westin Eriksson A; Meuller J; Cassel J; Saarinen G; Yuan ZQ; Löfberg C; Karlsson S; Sundqvist M; Whatling C
    J Med Chem; 2019 May; 62(9):4325-4349. PubMed ID: 30929436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 5‑lipoxygenase-specific sequence motif impedes enzyme activity and confers dependence on a partner protein.
    Schexnaydre EE; Gerstmeier J; Garscha U; Jordan PM; Werz O; Newcomer ME
    Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Apr; 1864(4):543-551. PubMed ID: 30291962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.
    Charleson S; Prasit P; Léger S; Gillard JW; Vickers PJ; Mancini JA; Charleson P; Guay J; Ford-Hutchinson AW; Evans JF
    Mol Pharmacol; 1992 May; 41(5):873-9. PubMed ID: 1588922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo .
    Chu J; Lauretti E; Di Meco A; Praticò D
    Transl Psychiatry; 2013 Dec; 3(12):e333. PubMed ID: 24301651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substituted 2,2-bisaryl-bicycloheptanes as novel and potent inhibitors of 5-lipoxygenase activating protein.
    Macdonald D; Brideau C; Chan CC; Falgueyret JP; Frenette R; Guay J; Hutchinson JH; Perrier H; Prasit P; Riendeau D; Tagari P; Thérien M; Young RN; Girard Y
    Bioorg Med Chem Lett; 2008 Mar; 18(6):2023-7. PubMed ID: 18276139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cloning, expression and characterization of mouse leukotriene C4 synthase.
    Lam BK; Penrose JF; Rokach J; Xu K; Baldasaro MH; Austen KF
    Eur J Biochem; 1996 Jun; 238(3):606-12. PubMed ID: 8706658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The binding of leukotriene biosynthesis inhibitors to site-directed mutants of human 5-lipoxygenase-activating protein.
    Mancini JA; Coppolino MG; Klassen JH; Charleson S; Vickers PJ
    Life Sci; 1994; 54(9):PL137-42. PubMed ID: 8114608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.
    Prasit P; Belley M; Blouin M; Brideau C; Chan C; Charleson S; Evans JF; Frenette R; Gauthier JY; Guay J
    J Lipid Mediat; 1993; 6(1-3):239-44. PubMed ID: 8357985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor.
    Stock NS; Bain G; Zunic J; Li Y; Ziff J; Roppe J; Santini A; Darlington J; Prodanovich P; King CD; Baccei C; Lee C; Rong H; Chapman C; Broadhead A; Lorrain D; Correa L; Hutchinson JH; Evans JF; Prasit P
    J Med Chem; 2011 Dec; 54(23):8013-29. PubMed ID: 22059882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
    Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological modulation of human platelet leukotriene C4-synthase.
    Sala A; Folco G; Henson PM; Murphy RC
    Biochem Pharmacol; 1997 Mar; 53(6):905-8. PubMed ID: 9113110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of AZD6642, an inhibitor of 5-lipoxygenase activating protein (FLAP) for the treatment of inflammatory diseases.
    Lemurell M; Ulander J; Winiwarter S; Dahlén A; Davidsson Ö; Emtenäs H; Broddefalk J; Swanson M; Hovdal D; Plowright AT; Pettersen A; Rydén-Landergren M; Barlind J; Llinas A; Herslöf M; Drmota T; Sigfridsson K; Moses S; Whatling C
    J Med Chem; 2015 Jan; 58(2):897-911. PubMed ID: 25478788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Arachidonic Acid and the Leukotriene Signaling Pathway on Vasculogenesis of Mouse Embryonic Stem Cells.
    Huang YH; Sharifpanah F; Becker S; Wartenberg M; Sauer H
    Cells Tissues Organs; 2016; 201(5):319-32. PubMed ID: 27198524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor.
    Kang KH; Liou HH; Hour MJ; Liou HC; Fu WM
    Neuropharmacology; 2013 Oct; 73():380-7. PubMed ID: 23800665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 5-lipoxygenase-activating protein is an arachidonate binding protein.
    Mancini JA; Abramovitz M; Cox ME; Wong E; Charleson S; Perrier H; Wang Z; Prasit P; Vickers PJ
    FEBS Lett; 1993 Mar; 318(3):277-81. PubMed ID: 8440384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents.
    De Simone R; Chini MG; Bruno I; Riccio R; Mueller D; Werz O; Bifulco G
    J Med Chem; 2011 Mar; 54(6):1565-75. PubMed ID: 21323313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP).
    Banoglu E; Çalişkan B; Luderer S; Eren G; Özkan Y; Altenhofen W; Weinigel C; Barz D; Gerstmeier J; Pergola C; Werz O
    Bioorg Med Chem; 2012 Jun; 20(12):3728-41. PubMed ID: 22607880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.